

News Release

5 August 2021

LiberoThera Secures 300 Million JPY Financing Agreement with Taiho Ventures

Tokyo, Japan, 5 August 2021 – LiberoThera Co., Ltd. (“LiberoThera”), a biotechnology company dedicated to the generation of new therapeutics targeting membrane proteins including G protein-coupled receptors (GPCRs), today announced the agreement of a 300 million JPY financial investment from Taiho Ventures, LLC (“Taiho Ventures”, Menlo Park, California). This additional financing brings LiberoThera’s total funding to 1.1 billion JPY. In conjunction with the financing, Sakae Asanuma, CFA, President and CEO at Taiho Ventures, will join the LiberoThera Board as a Director.

Founded on revolutionary research by Prof. Shigeyuki Yokoyama, Emeritus Professor at The University of Tokyo and Distinguished Senior Scientist at RIKEN, LiberoThera utilizes its cutting-edge cell-free protein expression system and non-natural amino acid technology to resolve the persistent obstacles to drug-based treatment of non-producible transmembrane proteins including some GPCR families. LiberoThera opens up an exciting new frontier in GPCR drug discovery through the development of first-in-class and best-in-class therapeutics.

About Taiho Ventures, LLC

Taiho Ventures, LLC is one of the corporate venture arms of Taiho Pharmaceutical Co., Ltd., a Japanese specialty pharmaceutical company focusing on oncology, allergy and immunology, and urology. For more information visit <https://taihoventures.com/>

About LiberoThera

LiberoThera is a drug discovery company targeting membrane proteins including GPCRs. The company was established in 2018 based on the novel membrane protein synthesis technologies invented at RIKEN which enable complexed membrane proteins to be prepared in natural forms with structural and functional integrity. LiberoThera is developing novel therapeutic candidates targeting physiologically important membrane proteins. For more information visit <https://www.liberothera.com/>

Media Contact

info@liberothera.com